Qi Wan

Qi Wan

Auto-generated profile, based on publicly available information

Qi Wan

Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
HTHuimin Tao
Huimin Tao
TWTeng Wang
Teng Wang
XDXin Dong
Xin Dong
QGQi Guo
Qi Guo
HXHuan Xu
Huan Xu
QWQi Wan
Qi Wan
Migraine is now ranked as the second most disabling disorder worldwide reported by the Global Burden of Disease Study 2016. As a noninvasive neurostimulation technique, transcutaneous electrical nerve stimulation(TENS) has been applied as an abortive and prophylactic treatment for migraine recently. We conduct this meta-analysis to analyze the effectiveness and safety of TENS on migraineurs. We searched Medline (via PubMed), Embase, the Cochrane Library and the Cochrane Central Register of Controlled Trials to identify randomized controlled trials, which compared the effect of TENS with sham TENS on migraineurs. Data were extracted and methodological quality assessed independently by two reviewers. Change in the number of monthly headache days, responder rate, painkiller intake, adverse events and satisfaction were extracted as outcome. Four studies were included in the quantitative analysis with 161 migraine patients in real TENS group and 115 in sham TENS group. We found significant reduction of monthly headache days (SMD: -0.48; 95% CI: -0.73 to − 0.23; P < 0.001) and painkiller intake (SMD: -0.78; 95% CI: -1.14 to − 0.42; P < 0.001). Responder rate (RR: 4.05; 95% CI: 2.06 to 7.97; P < 0.001) and satisfaction (RR: 1.85; 95% CI: 1.31 to 2,61; P < 0.001) were significantly increased compared with sham TENS. This meta-analysis suggests that TENS may serve as an effective and well-tolerated alternative for migraineurs. However, low quality of evidence prevents us from reaching definitive conclusions. Future well-designed RCTs are necessary to confirm and update the findings of this analysis. Our PROSPERO protocol registration number: CRD42018085984 . Registered 30 January 2018.

1 December 2021 in Brain Research Bulletin
Verified
Journal Article
Closed access
PZPinhuan Zhu
Pinhuan Zhu
XDXin Dong
Xin Dong
HXHuan Xu
Huan Xu
QWQi Wan
Qi Wan
QGQiqi Guo
Qiqi Guo
LYLanyun Yan
Lanyun Yan

1 December 2011 in Neuroscience Letters
Verified
Journal Article
Closed access
WWWenhui Wu
Wenhui Wu
QYQing Ye
Qing Ye
WWWenjuan Wang
Wenjuan Wang
LYLanYun Yan
LanYun Yan
QWQiang Wang
Qiang Wang
QWQi Wan
Qi Wan

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PGPing Gu
Ping Gu
CCCheng Chen
Cheng Chen
QWQian Wu
Qian Wu
CDChanghong Dong
Changhong Dong
TWTeng Wang
Teng Wang
XDXin Dong
Xin Dong
Background. Migraine has a great impact on public health. Current acute therapies do not satisfy all migraineurs. The novel serotonin 5‐HT1F receptor agonist appears more promising for aborting migraine attacks. Objective. To evaluate the clinical efficacy and safety of lasmiditan in treating acute migraine attacks. Methods. The literature search was performed in PubMed, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) which assessed the effect and safety of lasmiditan on migraine. The risk of bias was assessed using the Cochrane Collaboration’s risk of bias tool. Results were extracted and pooled as risk ratios (RRs) with a fixed or random‐effects model. Results. Based on the four included RCTs, pooled estimates showed that lasmiditan with the 50 mg, 100 mg, and 200 mg doses was superior to placebo at 2 h after the first dose in terms of pain freedom, absence of migraine‐associated symptoms, headache relief, no/mild disability, and global impression of change (very much/much better) (RRs ranged from 1.13 to 1.96), except for nausea‐free and vomiting‐free. Both lasmiditan 100 mg and 200 mg resulted in significantly fewer patients using rescue medication (100 mg: RR = 0.75, 95% CI (0.61, 0.92), P = 0.007; 200 mg: RR = 0.81, 95% CI (0.66, 0.99), P = 0.04) at 2‐24 h postdose, compared with placebo. Safety data showed that the proportion of patients reporting at least one treatment‐emergent adverse event (TEAE) and the incidence of most common TEAEs such as dizziness, paresthesia, fatigue, somnolence, and nausea was higher in the lasmiditan groups (50 mg, 100 mg, and 200 mg), compared with placebo. There was no significant difference between lasmiditan and placebo in terms of cardiovascular‐related TEAEs (RR = 2.75, 95% CI (0.81, 9.37), P = 0.11). Compared with lasmiditan 100 mg, lasmiditan 200 mg was more effective in pain freedom at 2 h after the first dose (RR = 0.83, 95% CI (0.74, 0.94), P = 0.004) but associated with a higher risk of reporting at least one TEAE (RR = 0.88, 95% CI (0.81, 0.96), P = 0.006). Conclusions. Lasmiditan with the 50 mg, 100 mg, and 200 mg doses are effective and safe in acute migraine treatment. Lasmiditan 200 mg is more effective than lasmiditan 100 mg in pain freedom, while lasmiditan 100 mg is better tolerated in the short‐term follow‐up. Further larger sample‐size RCTs are required to verify the applicability and tolerability in the long term.

19 October 2023 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
HTHuimin Tao
Huimin Tao
QWQi Wan
Qi Wan
MSMei Sun
Mei Sun
KCKefu Cai
Kefu Cai
YSYan Song
Yan Song
JSJiabing Shen
Jiabing Shen
Objectives: Patients with medication-overuse headache (MOH) are often complicated with anxiety, depression, and sleep disorders and are associated with dependence behavior and substance abuse. Melatonin has physiological properties including analgesia, regulation of circadian rhythms, soporific, and antidepressant and affects drug preference and addiction. This study aimed to investigate the role of melatonin in MOH compared with episodic migraine (EM) and healthy controls and to verify the relationship between plasma melatonin levels and psychiatric symptoms. Methods: Thirty patients affected by MOH, 30 patients with EM, and 30 matched healthy controls were enrolled. All subjects completed a detailed headache questionnaire and scales including the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index, the Leeds Dependence Questionnaire. Melatonin levels in plasma samples were measured by enzyme immunoassay method. Results: The levels of plasma melatonin were significantly different among 3 groups of subjects (MOH, 7.74 [5.40–9.89]; EM, 9.79 [8.23–10.62]; Control, 10.16 [8.60–17.57]; H = 13.433; P = 0.001). Significantly lower levels of melatonin were found in MOH patients compared with healthy controls (P = 0.001). The level of plasma melatonin inversely correlated with the scores of HADS-Anxiety (r = −0.318, P = 0.002), HADS-Depression (r = −0.368, P < 0.001), Pittsburgh Sleep Quality Index (r = −0.303, P = 0.004), and Leeds Dependence Questionnaire (r = −0.312, P = 0.003). Conclusions: This study innovatively detects the plasma melatonin levels in MOH patients and explores the association between melatonin levels and psychiatric symptoms. Melatonin may be potential complementary therapy in the treatment of MOH considering its comprehensive role in multiple aspects of MOH.